AstraZeneca may mount a challenge to GlaxoSmithKline’s three-in-one inhaler for chronic obstructive pulmonary disease (COPD) after a late-stage trial success. AZ’s single inhaler, PT010 ...

Patients with COPD had slightly more major adverse cardiovascular events after initiating single-inhaler triple therapy vs a LABA-ICS inhaler.

Large numbers of hospital admissions, along with poor adherence and the prescribing of inappropriate inhalers ... In COPD, 900,000 people have been diagnosed, while another 2.1 million have ...

[5] Packages containing 6 or 30 capsules with one inhaler device are available ... has not been studied in pediatric patients because COPD does not normally occur in children.

Together with a group of medical experts in Malaysia, the company held a Panel Discussion to review the burden and needs for COPD care ... fumarate) in one metered dose inhaler, Breztri Aerosphere ...

Inhalers and nebulizers play a key role in delivering medication to the lungs, making it easier for people with breathing ...

Inhaler misuse leading to inadequate medication delivery impacts a person's ability to manage symptoms of chronic obstructive ...